Developing drugs for central nervous system (CNS) disorders can be notoriously difficult. Indeed, a recent study by analysts at Informa’s BioMedTracker places the Probability of Technical Success (PTS) for a typical CNS asset in development (NME, non-NME, biologic, or vaccine) below that of oncology, women’s health, respiratory, ophthalmology, and immunology. Consequently, many biopharma companies have abandoned the category. Yet, others remain and even thrive by developing products that address unmet needs for a range of disorders characterized by a high social burden.
CNS Drug Development: The Landscape
A snapshot of the current CNS drug development landscape, looking at the key players and products, and the late-stage candidates with the greatest likelihood of approval.